Open Orphan plc will be rebranding to hVIVO plc on 26 October 2022, learn more here.

Compound Efficacy & VRM

Supporting discovery and pre-clinical compound efficacy

Compound Efficacy Assessment Services

hLab offer compound efficacy assessment services to support Discovery and Pre-clinical compound efficacy for anti-viral compounds; post challenge or vaccination assessment of generation of genetic variants and shifts in compound efficacy.hLab offer compound efficacy assessment services to support Discovery and Pre-clinical compound efficacy for anti-viral compounds; post challenge or vaccination assessment of generation of genetic variants and shifts in compound efficacy.

Includes:

  • Effective concentration 50% (EC50) (TCID50 and plaque reduction) determination for candidate antivirals against Coronavirus alpha and beta (OC43, 229E, SARS-CoV2), RSV A & B and FLU (H3N2 & H1N1) viruses

  • Comparison to medically relevant antiviral compounds available commercially

  • Compound efficacy against hVIVO GMP challenge viruses and a wide range of other relevant related viruses to inform study design

  • Shifts in compound efficacy assessed by EC50 and Next Generation Sequencing (NGS) for phenotypic and genotypic (variant analyses) antiviral resistance monitoring

If you’re a potential customer, job seeker, health professional or an investor, find out how hVIVO can help you.

Contact hVIVO
chevron-down